| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10963033 | Vaccine | 2015 | 14 Pages |
Abstract
First MMRV vaccine dose in children aged 10-24 months was associated with an elevated risk of seizure or febrile seizure. Further post-marketing restudies based on more rigorous study design are needed to confirm the findings.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Shu-Juan Ma, Yi-Quan Xiong, Li-Na Jiang, Qing Chen,